Clinical Trial Detail

NCT ID NCT01925131
Title S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Southwest Oncology Group
Indications

acute lymphocytic leukemia

Therapies

Cyclophosphamide + Prednisone + Vincristine

inotuzumab ozogamicin

Age Groups: adult

No variant requirements are available.